8-K: Viridian Therapeutics Secures $70M Upfront in Japan Licensing Deal for Thyroid Eye Disease Therapies

Viridian Therapeutics has entered into an exclusive collaboration and license agreement with Kissei Pharmaceutical for the development and commercialization of veligrotug and VRDN-003 in Japan, including an upfront payment of $70 million and potential milestones up to $315 million.

Summary

• Viridian Therapeutics and Kissei Pharmaceutical Co., Ltd. entered into a Collaboration and License Agreement on July 30, 2025.
• Viridian granted Kissei an exclusive license to develop and commercialize veligrotug and VRDN-003 in Japan for thyroid eye disease (TED).
• Viridian will receive an upfront payment of $70.0 million.
• Viridian is eligible to receive up to an additional $315.0 million upon the achievement of certain development, regulatory, and sales milestones.
• Viridian will also receive tiered royalties ranging from the twenties to the mid-thirties based on future net sales of licensed products in Japan.
• Kissei will be responsible for development, regulatory approval, and commercialization activities in Japan, including associated costs.
• Viridian will be responsible for manufacturing and supplying the licensed products for Kissei's developmental and commercial use in Japan, except in certain limited circumstances.
• Veligrotug (VRDN-001) has reported positive topline data from two global Phase 3 clinical trials (THRIVE and THRIVE-2), meeting all primary and secondary endpoints.
• VRDN-003 is a potential best-in-class, subcutaneous, half-life extended anti-IGF-1R antibody, currently in two ongoing global Phase 3 pivotal clinical trials (REVEAL-1 and REVEAL-2).

Sentiment

Score: 9

Explanation: The filing announces a significant collaboration agreement with a reputable partner, including a substantial upfront payment and potential future milestones and royalties. This provides non-dilutive funding, validates the company's assets, and expands market reach without direct operational burden in Japan, indicating strong positive momentum for Viridian Therapeutics.

Positives

• Secured a significant upfront payment of $70.0 million, providing immediate non-dilutive capital.
• Potential to receive up to an additional $315.0 million in development, regulatory, and sales milestone payments, offering substantial future revenue streams.
• Established a tiered royalty structure on net sales in Japan (20s to mid-30s percent), providing long-term revenue.
• Partnered with Kissei Pharmaceutical, a company with an established strong track record in successfully developing and commercializing in-licensed, rare disease medicines in Japan.
• Expanded market reach for veligrotug and VRDN-003 into Japan without direct development and commercialization costs in that region.
• Leveraged Kissei's expertise in rare diseases and local market knowledge for the Japanese market.
• Validated the potential of veligrotug and VRDN-003 through a competitive partnering process.

Negatives

• Granted exclusive development and commercialization rights for veligrotug and VRDN-003 in Japan, limiting direct participation in that market's upside beyond royalties and milestones.
• Retains manufacturing responsibility for products supplied to Kissei, which could entail ongoing costs and logistical complexities.

Risks

• Potential utility, efficacy, potency, safety, clinical benefits, clinical response, and convenience of product candidates may not be realized.
• Results or data from completed or ongoing clinical trials may not be representative of the results of ongoing or future clinical trials.
• Preliminary data may not be representative of final data.
• Uncertainty and potential delays related to clinical drug development.
• Timing of and ability to obtain and maintain regulatory approvals for therapeutic candidates.
• Competition from other therapies or products.
• Estimates of market size may be inaccurate.
• Future operating results and financial performance are subject to various uncertainties.
• Intellectual property position may not be sufficiently protected.
• Product candidates may not be commercially successful, if approved.
• Ability to achieve development, regulatory, and commercial milestone payments and receive royalties is not guaranteed.

Future Outlook

Viridian Therapeutics expects to advance veligrotug and VRDN-003 quickly for TED patients in Japan through the partnership with Kissei. The company anticipates achieving development, regulatory, and commercial milestone payments and receiving royalties from the commercial sale of these product candidates, if approved. They believe their product candidates have the potential to be best-in-class and address an unmet need in TED.

Management Comments

• "After running a very competitive partnering process, we are thrilled to partner with Kissei to bring these potential best-in-class medicines to TED patients in Japan." Steve Mahoney, Viridian's President and CEO.
• "Kissei has an established strong track record of successfully developing and commercializing in-licensed, rare disease medicines. Kissei shares our enthusiasm and commitment to these programs, and we believe Kissei is an ideal partner for us in Japan." Steve Mahoney, Viridian's President and CEO.
• "As we seek to further expand our pipeline in rare and intractable diseases, we are very excited by the potential of veligrotug and VRDN-003 to address the significant unmet needs of TED patients in Japan, based on veligrotug's strong and consistent phase 3 clinical data in THRIVE and THRIVE-2." Mutsuo Kanzawa, Chairman and CEO of Kissei.
• "This collaboration reinforces our mission to contribute to the health of people around the world through innovative pharmaceutical products, and we are committed to bringing important treatment options to Japanese patients as rapidly as possible." Mutsuo Kanzawa, Chairman and CEO of Kissei.

Industry Context

This collaboration highlights a common strategy in the biopharmaceutical industry where smaller, innovative companies partner with larger, established regional players to expand market access and leverage local development and commercialization expertise, particularly for specialized areas like rare diseases. The focus on Thyroid Eye Disease (TED) with IGF-1R antibodies indicates a growing therapeutic area with significant unmet needs, attracting both R&D and commercial interest.

Comparison to Industry Standards

• The upfront payment of $70 million and potential milestones of $315 million, totaling $385 million plus tiered royalties in the 20s to mid-30s, represent a substantial deal size for an exclusive regional license in the rare disease space, particularly for assets with positive Phase 3 data (veligrotug) and late-stage development (VRDN-003).
• Comparable deals in the rare disease or ophthalmology space often feature similar structures, with upfront payments reflecting the stage of development and market potential, and milestones tied to regulatory and commercial achievements. For instance, other companies developing TED treatments, such as Horizon Therapeutics (now Amgen) with Tepezza (teprotumumab), have demonstrated the significant market value of effective therapies in this area, setting a high bar for potential commercial success.
• The partnership with Kissei, a Japanese pharmaceutical company with a focus on rare/intractable diseases, aligns with industry trends of seeking partners with established local infrastructure and regulatory experience for specific geographic markets.

Stakeholder Impact

• Shareholders: Positive impact due to significant non-dilutive funding, potential for future revenue streams, validation of pipeline assets, and expanded market access.
• Employees: Potential for continued growth and stability within the company due to strengthened financial position and pipeline advancement.
• Patients (in Japan): Potential for new treatment options for Thyroid Eye Disease (TED) to become available more rapidly through Kissei's local development and commercialization efforts.

Next Steps

• Kissei to develop and seek regulatory approval for veligrotug and VRDN-003 in Japan.
• Kissei to commercialize licensed products in Japan following regulatory approval.
• Viridian to file the Collaboration Agreement as an exhibit to its Quarterly Report on Form 10-Q for the period ended September 30, 2025.
• Advance VRDN-003 through ongoing global Phase 3 pivotal clinical trials (REVEAL-1 and REVEAL-2).
• Continue advancing the novel portfolio of neonatal Fc receptor (FcRn) inhibitors (VRDN-006 and VRDN-008).

Key Dates

Recommendation

The collaboration agreement with Kissei Pharmaceutical is a highly positive development for Viridian Therapeutics. The $70 million upfront payment provides immediate, non-dilutive capital, significantly strengthening the company's financial position. The potential for an additional $315 million in milestone payments, coupled with tiered royalties in the 20s to mid-30s on net sales in Japan, represents substantial future revenue opportunities. This deal validates the company's lead assets, veligrotug and VRDN-003, and expands their market reach into Japan through an experienced partner, mitigating direct operational and financial risks in that region. Given the strong clinical data for veligrotug and the advanced stage of VRDN-003, this partnership de-risks the commercialization pathway in a key market and enhances the overall value proposition of Viridian's pipeline. This strategic move positions the company for significant long-term growth and is likely to be viewed very favorably by the market.

Keywords

Viridian Therapeutics, Kissei Pharmaceutical, Collaboration Agreement, License Agreement, Thyroid Eye Disease, TED, veligrotug, VRDN-001, VRDN-003, IGF-1R antibody, Biopharmaceutical, Rare Diseases, Drug Development, Commercialization, Japan, Milestone Payments, Royalties, Clinical Trials, THRIVE, REVEAL